Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

46.62 +0.59 (+1.28%)

Official Closing Price Updated: 4:15 PM EDT, Mar 26, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	2,218,259
Open	46.33
Bid (Size)	46.69 (200)
Ask (Size)	47.74 (200)
Prev. Close	46.03
Today's Range	46.25 - 47.15
52wk Range	43.32 - 56.93
Shares Outstanding	1,250,690,553
Dividend Yield	4.74%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Sarepta Therapeutics (SRPT) Stock Surges 34.98% on Breakthrough Clinical Data

Today 10:11 EDT

CAMBRIDGE, MA — March 26, 2026 — Shares of Sarepta Therapeutics (NASDAQ:SRPT) skyrocketed 34.98% in heavy trading today, marking the biotech giant's most explosive single-day gain in over two years....

Via MarketMinute

The Brain Barrier Broken: Inside Denali Therapeutics’ Landmark FDA Approval of AVLAYAH

Today 10:07 EDT

On March 25, 2026, the landscape of neurodegenerative medicine underwent a seismic shift. The U.S. Food and Drug Administration (FDA) granted accelerated approval to Denali Therapeutics (NASDAQ: DNLI)...

Via Finterra

Performance

YTD	-3.3%	-3.3%
1 Month	-1.3%	-1.3%
3 Month	-3.6%	-3.6%
6 Month	+0.5%	+0.5%
1 Year	-15.9%	-15.9%

More News

Sanofi ADR (NASDAQ:SNY) Presents a Classic Value Investment Case ↗

March 25, 2026

Via Chartmill

Sanofi (NASDAQ:SNY) Emerges as a Top Dividend Stock from Methodical Screening ↗

March 11, 2026

Via Chartmill

Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)

March 24, 2026

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Does This $25 Million Bet on a Stock Down 61% Signal Turnaround Potential at $6? ↗

March 20, 2026

Via The Motley Fool

The mRNA Renaissance: Moderna’s 83% Surge Leads the 2026 Healthcare Recovery

March 16, 2026

Via MarketMinute

Complementing the Future: A Deep Dive into Dianthus Therapeutics (DNTH) After Its Phase 3 Breakthrough

March 12, 2026

Via Finterra

DNTH Stock Soars After Early ‘Go’ Decision For Drug In Autoimmune Disorder Program, Boosting Wall Street Optimism For Potential Launch ↗

March 09, 2026

Via Stocktwits

The Moderna Pivot: Analyzing the 14% Surge and the Future of mRNA Oncology

March 06, 2026

Via Finterra

The Best Healthcare Stock to Invest $1,000 in Right Now ↗

March 02, 2026

Via The Motley Fool

The Great Pivot: Inside Novavax’s 2026 Turnaround and the Road to Combination Vaccines

February 27, 2026

Via Finterra

AstraZeneca’s Strategic Leap: Pharmaceutical Giant Completes Historic Move to the New York Stock Exchange

February 26, 2026

Via MarketMinute

European Commission Grants Marketing Authorization to Cytokinetics for Cardiac Drug MYQORZO

February 23, 2026

Via MarketMinute

1 No-Brainer Biotech Stock To Buy Today and Never Sell ↗

February 21, 2026

Via The Motley Fool

Moderna’s mRNA Renaissance: Navigating Volatility and the Post-Pandemic Pipeline

February 17, 2026

Via Finterra

Sanofi Tightens Grip on Ocular Therapeutix with Revised Bid as Pivotal SOL-1 Trial Results Loom

February 16, 2026

Via MarketMinute

Alnylam Pharmaceuticals (ALNY): The RNAi Pioneer’s 2026 Breakout and the Battle for Cardiovascular Dominance

February 12, 2026

Via Finterra

FDA Stuns Moderna with Refusal to Review Flu Vaccine, Sending Shares Tumbling 3.5%

February 12, 2026

Via MarketMinute

This Infrastructure Stock Surged Nearly 40% in One Year -- and One Fund Sold $11 Million in Shares ↗

January 29, 2026

Via The Motley Fool

Lilly Bolsters Immunology Arsenal with $1.2 Billion Acquisition of Ventyx Biosciences

January 28, 2026

Via MarketMinute

Eli Lilly Reinforces Immunology Dominance with $1.2 Billion Acquisition of Ventyx Biosciences

January 27, 2026

Via MarketMinute

Nasdaq, S&P 500 Futures Subdued Ahead Of PMI Data: Why INTC, TSLA, NFLX, VST, MOVE Are On Traders' Radar Today ↗

January 23, 2026

Via Stocktwits

AstraZeneca Signals End of an Era: Formal Move to NYSE Triggers Major Index Rebalancing

January 20, 2026

Via MarketMinute

GSK Challenges Xolair Dominance with $2.2 Billion Acquisition of RAPT Therapeutics

January 20, 2026

Via MarketMinute

Frequently Asked Questions

Is Sanofi - American Depositary Shares publicly traded?

Yes, Sanofi - American Depositary Shares is publicly traded.

What exchange does Sanofi - American Depositary Shares trade on?

Sanofi - American Depositary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Sanofi - American Depositary Shares?

The ticker symbol for Sanofi - American Depositary Shares is SNY on the Nasdaq Stock Market

What is the current price of Sanofi - American Depositary Shares?

The current price of Sanofi - American Depositary Shares is 46.62

When was Sanofi - American Depositary Shares last traded?

The last trade of Sanofi - American Depositary Shares was at 03/26/26 04:15 PM ET

What is the market capitalization of Sanofi - American Depositary Shares?

The market capitalization of Sanofi - American Depositary Shares is 58.31B

How many shares of Sanofi - American Depositary Shares are outstanding?

Sanofi - American Depositary Shares has 58B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.